Autologous blood- and bone marrow-derived stem cell therapy uses cells isolated from a patient's own blood or bone marrow to promote the recovery of damaged tissue. Unlike medications or injections that block pain signals, it works by awakening the body's own regenerative mechanisms. However, the indications and level of evidence vary by field, so before deciding on this treatment, patients should weigh both what has been established so far and what remains unknown.
The cells used in this therapy fall into two categories: hematopoietic stem cells (stem cells that develop into blood cells) and mesenchymal stem cells (stem cells that can differentiate into connective tissues such as bone, cartilage, fat, and muscle). Hematopoietic stem cells are mobilized with agents such as G-CSF and then collected from peripheral blood, or aspirated directly from the bone marrow, while mesenchymal stem cells are usually isolated from bone marrow aspirate or fat tissue. Because the cells come from the patient's own body, the risk of immune rejection seen with tissue transplanted from another person is relatively low.
These cells work in two ways. One is differentiation: at the site of injury, they transform into the cell type needed to fill the defect. The other is secretion: they release growth factors and cytokines that calm surrounding inflammation, promote the growth of new blood vessels, and stimulate the resident cells at that site to resume their function.
What the clinic emphasizes is the direction of the goal. Pain medications or nerve blocks reduce pain signals, but the underlying tissue damage often remains unchanged. The stem cell approach attempts to change the tissue environment itself that is the source of the pain. This distinction does not change everything about the treatment, but it offers a useful framework for patients to understand what is happening in their own body.
When Is It Considered
It's difficult to summarize the indications in a single sentence. The level of evidence differs by condition, and even within the same condition, the decision differs from patient to patient.
Areas with relatively solid clinical data are vascular conditions with limited existing treatment options, such as critical limb ischemia (a condition where the blood vessels supplying the leg are blocked, putting tissue at risk of necrosis). In patients for whom bypass surgery is difficult or who don't respond adequately to medication, attempts to inject autologous bone marrow-derived cells into the ischemic area to induce new blood vessel growth have continued for decades. Application is also under review in fields where tissue regeneration is the treatment goal, such as chronic musculoskeletal injury, and clinical trials in neurodegenerative disease are ongoing as well, though the evidence level remains limited so far.
In pain medicine practice, this treatment generally comes under consideration in two situations. One is when it's too early to move to surgery, but conservative approaches such as nerve blocks, physical therapy, and extracorporeal shock wave therapy have been tried sufficiently for six months or more without satisfactory improvement. The other is when surgery itself is burdensome because of the patient's age, underlying conditions, or lifestyle. When conservative treatment doesn't produce sufficient improvement, an additional approach aimed at tissue regeneration may be considered.
The word "indication" needs some caution, though. For some conditions, evidence exists at the meta-analysis level, while for others it remains at the level of small observational studies. Knee osteoarthritis and critical limb ischemia have relatively solid evidence, whereas chronic low back pain and neurodegenerative disease are still at the observational-study stage. This means that even under the same name, "stem cell therapy," the weight of evidence behind it varies widely. Before deciding on treatment, the site of injury, degree of injury, response to prior treatment, and overall health status need to be assessed one by one.
Procedure Method and Combination with Other Treatments
The procedure generally proceeds in three stages: obtaining cells, separating and concentrating them, and injecting them into the lesion.
To obtain cells, the clinician draws blood from an arm vein, or aspirates bone marrow from the back of the pelvic bone (iliac crest) after local anesthesia. Bone marrow aspiration tends to be the part patients worry about most; procedure time and needle depth vary depending on body type, collection site, and preparation method, so it is worth confirming these details with the treating physician beforehand. The collected sample is placed in a centrifuge to separate plasma, red blood cells, and the stem-cell-rich layer. The needed layer is drawn off, the cell count is measured, the cells are concentrated, and they are then injected precisely into the lesion under ultrasound or imaging guidance.
The starting point for combination treatment design is that this therapy is not used alone. Nerve blocks quickly calm acute inflammation and pain, extracorporeal shock wave therapy delivers physical stimulation to damaged tissue to awaken the healing response, and ultrasound-guided injections target the lesion location precisely. Stem cell injection adds a further layer of tissue regeneration on top of these.
The most common mistake in combination treatment involves sequence and timing intervals. Using strong anti-inflammatory medication for an extended period immediately after injection may interfere with the process by which cells survive and establish themselves (engraftment). Extracorporeal shock wave therapy also carries a different meaning depending on whether it is used right before injection or two to three weeks afterward. Research has reported that the design of timing and intervals affects treatment response.
When planning the procedure, the physician builds the overall schedule around the patient's imaging findings, prior treatment history, and target timeline for returning to daily activities. If patients also organize their return-to-activity goals, current medications, and prior treatment history before the consultation, a more precise plan becomes possible. It is more accurate to understand this not as a single injection but as one component of a recovery plan spanning several months.
Effects and Limitations Identified So Far
When discussing effectiveness, definitive claims should be avoided. This is not only academically sound but also a basic responsibility toward patients.
Clinical data gathered so far show that pain reduction and functional improvement have been reported for certain indications. For knee osteoarthritis, some tendon injuries, and critical limb ischemia, trials have accumulated showing improvements in pain scores, walking distance, and joint function measures before and after injection. For some indications, related meta-analyses have been published, and reported adverse events have generally been mild. Because outcomes may vary depending on individual condition, patients should consult thoroughly with their physician before undergoing the procedure.
The limitations are clear. Large-scale randomized controlled trials, especially long-term follow-up data spanning 10 years or more, remain scarce. Results vary depending on the cell preparation method—where and how the cells are harvested and how much they are concentrated—and there is also considerable variation depending on the injection route, injection volume, and patient selection criteria. This means that a treatment carrying the same name may actually follow a slightly different protocol from one paper to another. Discussions on standardization continue within the academic community.
How this treatment is explained in the clinic also differs accordingly. Rather than simply saying that "improvement is reported," the clinic conveys the distinction to patients as it is: "some degree of improvement is reported," and "the evidence is solid for this indication, while for that one it is still at the level of observational studies." Setting expectations at an appropriate level helps patients stay steady through the recovery process after treatment. Treatment effects and side effects may vary depending on individual condition.
Ongoing research is moving toward cell culture techniques, standardized formulations, and protocols tailored to specific lesions. There is a possibility that the map of indications will become more precise in the coming years. What matters is that, at this point in time, patients choosing a treatment weigh its effects and limitations equally when making their decision.
References
- Hoang Duc M, Pham Phuong T, Bach Trung Q (2022). Stem cell-based therapy for human diseases.. Signal Transduct Target Ther. PMID: 35933430
- Rodríguez-Eguren Adolfo, Bueno-Fernandez Clara, Gómez-Álvarez María (2024). Evolution of biotechnological advances and regenerative therapies for endometrial disorders: a systematic review.. Hum Reprod Update. PMID: 38796750
Frequently Asked Questions
Q. How long does it take to return to daily life after blood stem cell treatment?
On the day of collection and injection, resting the treated area is recommended, and most patients return to light daily activities within 1 to 3 days. When bone marrow collection is involved, dull discomfort at the collection site may persist for several days, and the timing for resuming vigorous exercise or physically demanding work should be worked out individually with the treating physician. Recovery can vary from person to person.
Q. When does the treatment effect appear after the procedure?
The process by which cells trigger tissue-regeneration signals unfolds over weeks to months, so you should not expect an immediate change right after the injection. Clinical studies typically evaluate changes in pain and functional measures starting around 4 to 12 weeks, and it is not uncommon for the peak effect to appear only at 3 to 6 months. The timing of the response varies from person to person, and in some patients the change may not be clearly noticeable, so follow your scheduled follow-up visits and discuss your progress with your physician.
Q. Can this be combined with existing nerve block treatment or PRP therapy?
Combining treatments is possible, and clinical practice has tried designs in which a nerve block first calms acute inflammation before stem cells are injected, or in which stem cells are applied sequentially with PRP. However, the order and interval used to combine treatments can affect outcomes, so an individualized plan is needed that takes into account the purpose of each treatment and the patient's condition. For example, patients are sometimes advised to avoid strong anti-inflammatory drugs for a certain period after injection, but the specific interval and combination design should be discussed with the treating physician.
Q. Does giving repeat injections at short intervals increase the effect?
Current evidence does not support the idea that repeat injections given at short intervals simply add up to a greater effect. Clinicians typically evaluate the tissue response and symptom changes over a period of several months after the first injection before deciding whether to give another dose, and repeating the treatment without sufficient observation may lead to an unnecessary procedural burden.
Q. Can elderly patients or those with chronic conditions receive this treatment?
Age alone is not an absolute contraindication, but clinicians do take into account that the number and activity of harvested cells may decrease with advancing age. The risk level of the collection process and the quality of the cells can vary depending on underlying conditions such as anticoagulant use, blood disorders, or active infection, so an overall health assessment should come before the procedure.